Detalhe da pesquisa
1.
Clinical value of next-generation sequencing compared to cytogenetics in patients with suspected myelodysplastic syndrome.
Br J Haematol
; 192(4): 729-736, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32588428
2.
Filgrastim-Stimulated Bone Marrow Compared with Filgrastim-Mobilized Peripheral Blood in Myeloablative Sibling Allografting for Patients with Hematologic Malignancies: A Randomized Canadian Blood and Marrow Transplant Group Study.
Biol Blood Marrow Transplant
; 22(8): 1410-1415, 2016 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-27154847
3.
Phase II study of targeted therapy with temozolomide in acute myeloid leukaemia and high-risk myelodysplastic syndrome patients pre-screened for low O(6) -methylguanine DNA methyltransferase expression.
Br J Haematol
; 167(5): 664-70, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25160658
4.
Predictors of unsuccessful mobilization with granulocyte colony-stimulating factor alone in patients undergoing autologous hematopoietic stem cell transplantation.
J Clin Apher
; 28(4): 285-92, 2013 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-23426584
5.
Erratum to "Filgrastim-Stimulated Bone Marrow Compared with Filgrastim-Mobilized Peripheral Blood in Myeloablative Sibling Allografting for Patients with Hematologic Malignancies: A Randomized Canadian Blood and Marrow Transplant Group Study" [Biol Blood Marrow Transplant 2016;22:1410-1415].
Biol Blood Marrow Transplant
; 23(3): 534, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-27789277
6.
Reducing cytogenetic testing in the era of next generation sequencing: Are we choosing wisely?
Int J Lab Hematol
; 44(2): 333-341, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-34713980
7.
Hodgkin lymphoma with cutaneous involvement.
Dermatol Online J
; 15(5): 5, 2009 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-19624983
8.
Response to "Need to minimize bias when surveying patient attitudes to stopping cml treatment".
Curr Oncol
; 21(6): e803-4, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25489271
9.
Effect of the addition of rituximab to salvage chemotherapy prior to autologous stem cell transplant in aggressive CD20+ lymphoma: a cohort comparison from the NCIC Clinical Trials Group Study LY.12.
Leuk Lymphoma
; 58(1): 64-69, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27266754
10.
Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant.
Clin Cancer Res
; 10(24): 8170-6, 2004 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-15623591
11.
Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12.
J Clin Oncol
; 32(31): 3490-6, 2014 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25267740
12.
Sunitinib malate in patients with intermediate-2 or high-risk myelodysplastic syndrome or chronic myelomonocytic leukemia.
Leuk Lymphoma
; 55(11): 2669-71, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-24611649
13.
Posterior reversible encephalopathy syndrome in a patient with multiple myeloma treated with thalidomide.
Leuk Lymphoma
; 53(5): 1003-5, 2012 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-22054288
14.
High-Dose Chemotherapy Followed by Peripheral and/or Bone Marrow Stem Cell Transplant in Patients With Advanced Sarcoma: Experience of a Canadian Centre.
Sarcoma
; 8(2-3): 63-9, 2004.
Artigo
em Inglês
| MEDLINE | ID: mdl-18521397
15.
An evaluation of the donor experience in the canadian multicenter randomized trial of bone marrow versus peripheral blood allografting.
Biol Blood Marrow Transplant
; 10(6): 405-14, 2004 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-15148494
16.
A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies.
Blood
; 100(5): 1525-31, 2002 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-12176866
17.
Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG).
Cancer
; 101(8): 1835-42, 2004 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-15386331